Why the Keytone Dairy (ASX:KTD) share price is up 8% today

The Keytone Dairy Corporation Ltd (ASX: KTD) share price is rocketing today due to a deal with Coles Group Ltd (ASX: COL).

| More on:
dairy asx share price represented by happy looking cow close up

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Keytone Dairy Corporation Ltd (ASX: KTD) share price is on fire today, up 8.12% to 26 cents at the time of writing. Keytone shares closed at 24 cents on Friday afternoon, but opened at 26 cents this morning and were up to 28 cents at one point, a rise of more than 16% at the time.

Despite this strong showing today, Keytone isn't having a great year in terms of share price performance. Keytone shares remain down 33% year to date on this pricing, and down more than 40% from the highs of 46 cents we saw back in mid-April.

So why is this dairy company seemingly in investors' good books today?

Why the Keytone share price is surging today

Today's Keytone share price performance is most likely due to an ASX release the company provided just before market open this morning. In this announcement, Keytone revealed it has inked a significant deal with major supermarket operator Coles Group Ltd (ASX: COL).

Keytone will provide private-label goods to Coles that will be sold under Coles' 'in-house' white-label brands under the agreement. The products to be provided under this arrangement are "multiple powdered SKUs [stock keeping units] in various pack formats, flavours and sizes". Keytone told the markets the deal is a result of the company's "first-class manufacturing facilities and rigorous health and safety standards, highly responsive and innovative new product development team and the growing strategic relationship between Keytone and Coles".

Production of goods under the deal is expected to commence "late in the first quarter of 2021", with the products set to appear in Coles' stores "from the second quarter of 2021". The company tells investors the "term of the arrangement has not been specified". However, Keytone "anticipates the term will be longer than an initial 12 month period, implying a gross sales value multiples higher than the annual value".

The company forecasts the deal will result in $5.2 million worth of sales per year.

Keytone CEO, Danny Rotman, had this to say on the announcement:

This is a fantastic and significant win for the business. It highlights the growing awareness of the Keytone brand of quality and our credentials across the broader health and wellness sector… The calibre of the client base is becoming increasingly robust and we look forward to supporting the growth of our diversified customer base through our state of the art facilities and first-class product development and operations teams.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of COLESGROUP DEF SET. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Two boys play outside on an old army tank.
Opinions

What's next on the horizon for EOS? Why I think 2026 could be massive

EOS is entering a new growth phase, with a growing backlog, deep pipeline, and multiple large defence contracts on the…

Read more »

A happy man and woman sit having a coffee in a cafe while she holds up her phone to show him the ASX shares that did best today.
Share Market News

NEXTDC lifts contracted utilisation and order book in December update

NEXTDC has ramped up its contracted utilisation and forward order book, flagging ongoing revenue growth over the next several years.

Read more »

Successful group of people applauding in a business meeting and looking very happy.
Share Market News

Telix Pharmaceuticals in focus with China trial success and FDA updates

Telix Pharmaceuticals posts positive China Phase 3 results for Illuccix and advances its FDA applications.

Read more »

Two smiling work colleagues discuss an investment at their office.
Share Market News

Monadelphous wins $250m Rio Tinto contract: What it means for shareholders

Monadelphous shares are in the spotlight after a $250 million construction contract win with Rio Tinto.

Read more »

A man sits in deep thought with a pen held to his lips as he ponders his computer screen with a laptop open next to him on his desk in a home office environment.
Share Market News

Spark New Zealand cuts debt by $240m via Challenger financing deal

Spark New Zealand reduces debt by $240m with a new receivables financing partnership with Challenger to support mobile growth.

Read more »

A man sits in deep thought with a pen held to his lips as he ponders his computer screen with a laptop open next to him on his desk in a home office environment.
Technology Shares

Why I think these 3 ASX shares are top-quality buying at today's prices

These 3 high-quality ASX shares have fallen out of favour. I think they all look attractive at today’s prices.

Read more »

Smiling man with phone in wheelchair watching stocks and trends on computer
Share Market News

5 things to watch on the ASX 200 on Monday

It looks set to be a decent start to the week for Aussie investors.

Read more »

A man in a business suit whose face isn't shown hands over two australian hundred dollar notes from a pile of notes in his other hand to an outstretched hand of another person.
Opinions

2 strong Australian stocks to buy now with $5,000!

I’m excited by the potential of these two businesses.

Read more »